DWP212525 / Daewoong Pharma - LARVOL DELTA

A Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase 1 Clinical Tiral in Healthy Male Volunteers (clinicaltrials.gov) - P1 | N=76 | Recruiting | Sponsor: Daewoong Pharmaceutical Co. LTD.

New P1 trial • Immunology

Daewoong Pharmaceutical, new drug for autoimmune disease treatment 'DWP212525' enters clinical trial [Google translation] (Health Korea News) - "Daewoong Pharmaceutical received approval for the Phase 1 clinical trial plan (IND) for 'DWP212525' from the Ministry of Food and Drug Safety on the 25th. The test is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic characteristics of 'DWP212525' on healthy adult male volunteers. The clinical institution is Seoul National University Hospital."

New P1 trial • Atopic Dermatitis • Immunology • Inflammatory Bowel Disease • Rheumatoid Arthritis